Mer­ck­'s big ADC move; Lat­est from #ES­MO23; How Eli Lil­ly is think­ing about deals; AI-de­signed drugs face reck­on­ing in clin­ic; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As Rey­nald Cas­tañe­da, Kyle LaHu­cik and Lei Lei Wu bring us the lat­est ES­MO news out of Madrid, don’t for­get to sign up for our vir­tu­al event on Mon­day to get the ex­perts’ take on where can­cer re­search is now and where we are head­ed next.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER